210 related articles for article (PubMed ID: 10759774)
1. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase.
Rafati S; Baba AA; Bakhshayesh M; Vafa M
Clin Exp Immunol; 2000 Apr; 120(1):134-8. PubMed ID: 10759774
[TBL] [Abstract][Full Text] [Related]
2. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.
Soong L; Duboise SM; Kima P; McMahon-Pratt D
Infect Immun; 1995 Sep; 63(9):3559-66. PubMed ID: 7642292
[TBL] [Abstract][Full Text] [Related]
3. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
[TBL] [Abstract][Full Text] [Related]
4. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
[TBL] [Abstract][Full Text] [Related]
5. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major.
Rafati S; Salmanian AH; Taheri T; Vafa M; Fasel N
Vaccine; 2001 May; 19(25-26):3369-75. PubMed ID: 11348700
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
[TBL] [Abstract][Full Text] [Related]
9. Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis.
Rafati S; Couty-Jouve S; Alimohammadian MH; Louis JA
Clin Exp Immunol; 1997 Nov; 110(2):203-11. PubMed ID: 9367403
[TBL] [Abstract][Full Text] [Related]
10. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
[TBL] [Abstract][Full Text] [Related]
11. Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation.
Rafati S; Kariminia A; Seyde-Eslami S; Narimani M; Taheri T; Lebbatard M
Vaccine; 2002 Jun; 20(19-20):2439-47. PubMed ID: 12057598
[TBL] [Abstract][Full Text] [Related]
12. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
[TBL] [Abstract][Full Text] [Related]
13. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
Coler RN; Skeiky YA; Bernards K; Greeson K; Carter D; Cornellison CD; Modabber F; Campos-Neto A; Reed SG
Infect Immun; 2002 Aug; 70(8):4215-25. PubMed ID: 12117930
[TBL] [Abstract][Full Text] [Related]
14. DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant.
Bayih AG; Daifalla NS; Gedamu L
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3391. PubMed ID: 25500571
[TBL] [Abstract][Full Text] [Related]
15. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice.
Doroud D; Zahedifard F; Vatanara A; Taslimi Y; Vahabpour R; Torkashvand F; Vaziri B; Rouholamini Najafabadi A; Rafati S
PLoS Negl Trop Dis; 2011 Jul; 5(7):e1236. PubMed ID: 21765963
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages.
Shimizu Y; Takagi H; Nakayama T; Yamakami K; Tadakuma T; Yokoyama N; Kojima N
Parasite Immunol; 2007 May; 29(5):229-39. PubMed ID: 17430546
[TBL] [Abstract][Full Text] [Related]
18. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.
Al-Wabel MA; Tonui WK; Cui L; Martin SK; Titus RG
Am J Trop Med Hyg; 2007 Dec; 77(6):1060-5. PubMed ID: 18165522
[TBL] [Abstract][Full Text] [Related]
19. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
Tonui WK; Titus RG
Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
[TBL] [Abstract][Full Text] [Related]
20. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.
Lakhal-Naouar I; Koles N; Rao M; Morrison EB; Childs JM; Alving CR; Aronson NE
Vaccine; 2019 Jan; 37(3):516-523. PubMed ID: 30528328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
